Despite high use of continuous glucose monitoring and insulin pump therapy, fear of hypoglycemia (low blood sugar) remains a significant barrier to physical activity and exercise for adults with type 1 diabetes (T1D), according to new research to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).
Sarepta’s gene therapy to be manufactured at Catalent plant with ‘operational challenges’ this spring
Catalent, the contract manufacturer in the process of overhauling its operations, is manufacturing Sarepta Therapeutics’ newly approved gene therapy for Duchenne muscular dystrophy at one
June 24, 2023